Drugs / PASIFOLATE EXATECAN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05622591 | Jun 2024 | childhood acute myeloid leukemia | Elucida Oncology | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05001282 | Sep 2021 → Jun 2024 | endometrial clear cell adenocarcinoma, endometrioid adenocarcinoma, endometrioid tumor, fallopian tube cancer +3 | Elucida Oncology | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PASIFOLATE EXATECAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068463 ↗ |
| Known as | ELU001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05001282 ↗ |
| Modality | Other / unclassified | “Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)” NCT05622591 ↗ |